University of Yamanashi · Division of Medicine / Faculty of Medicine

Research keywordsthoracic oncology・non-small cell lung cancer・small cell lung cancer・immune checkpoint inhibitors・ALK targeted therapy・durvalumab・EGFR inhibitor resistance・circulating tumor DNA・pulmonary aspergillosis

This is a public-data preview. Personalized fit, contact angles, and saved workflows require sign-in.

• Comparison of immune checkpoint inhibitor plus chemotherapy or ipilimumab plus nivolumab-based therapy for NSCLC patients with PD-L1 TPS (1-49 %): TOPGAN2023-01.2023 · 論文
• 3期非小細胞肺癌に対する化学放射線治療のICI維持療法中に筋炎を生じ、2年後に重症筋無力症を発症した一例2022 · 日本結核・非結核性抗酸菌症学会関東支部学会・日本呼吸器学会関東地方会合同学会プログラム・抄録集 181回・248回 36 - 36 2022年2月
• A case of non-neutropenic invasive pulmonary aspergillosis under immune checkpoint inhibitor therapy for malignant melanoma2022 · Respiratory Medicine Case Reports 2022年3月 ( ISSN： 2213-0071 )
• Subsequent treatment for locally advanced non-small-cell lung cancer that progressed after definitive chemoradiotherapy and consolidation therapy with durvalumab: a multicenter retrospective analysis (TOPGAN 2021-02)2021 · 論文

• Official profile